Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

This article is part of the supplement: Sepsis 2012

Poster presentation

Role of TREM-1 in endothelial dysfunction during experimental sepsis

A Boufenzer1*, N Sennoun1, Y Bouazza1, M Derive1, PE Bollaert2 and S Gibot2

  • * Corresponding author: A Boufenzer

Author Affiliations

1 Groupe CHOC - Inserm U961, Nancy University, Nancy, France

2 CHU Nancy, France

For all author emails, please log on.

Critical Care 2012, 16(Suppl 3):P49  doi:10.1186/cc11736


The electronic version of this article is the complete one and can be found online at: http://ccforum.com/content/16/S3/P49


Published:14 November 2012

© 2012 Boufenzer et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a receptor of the immunoglobulin superfamily expressed on the surface of neutrophils and monocytes/macrophages. It plays an important role during sepsis by amplifying the inflammatory response. Modulation of TREM-1 through the administration of a short synthetic peptide (LR12) increases survival during experimental sepsis. This study aimed to explore the mechanisms by which LR12 prevented sepsis-induced cardiovascular dysfunction.

Methods

We studied the effect of TREM-1 modulation by a synthetic peptide LR12 (3 mg/kg) on MAP and blood lactate during experimental sepsis (CLP). Aortic and mesenteric arterial vessels of these animals were collected to study the vasoreactivity to phenylephrine (Phe) and acetylcholine (Ach) ex vivo (Myograph). Alternatively, vasoreactivity was studied in the vessels of healthy animals (with and without endothelial lawyer) stimulated with LPS or with a specific agonist of TREM-1 (αTREM-1, 10 μg/ml), with or without LR12 (20 mg/ml). The effect of LR12 on arterial vessels was also studied through western blotting (eNOS, iNOS, Akt, COX-1, COX-2) and qRT-PCR. Mouse lung microvascular endothelial cells (LUMECs; CD146+) were analyzed by flow cytometry, qRT-PCR, and ELISA to decipher the effect of LR12 on LPS-induced endothelial activation.

Results

CLP induced MAP decrease and lactate elevation were prevented by the administration of LR12. Arterial vessels from septic animals treated with LR12 showed better response to Phe and Ach compared with controls. The reactivity of aortic and mesenteric vessels (contraction and relaxation) stimulated in vitro with LPS or by αTREM-1 was altered: this phenomenon was reversed by LR12. LR12 restored the phosphorylation of Akt and eNOS while it reduced the activation of inducible pathways (iNOS, COX-2). FACS analysis showed that TREM-1 is constitutively expressed by LUMECs (CD146+/VEGFR2+). In vivo, the expression of Trem-1 was increased in septic animals and was inducible in vitro upon stimulation with LPS. Trem-1, Tnf-α and Il-6 expression was upregulated by LPS; once again LR12 attenuated this upregulation. Finally, the production of several cytokines by LPS-stimulated LUMECs was decreased by LR12.

Conclusion

Here we show that TREM-1 is expressed on endothelial cells from the aorta, mesenteric artery, and microvascular endothelial cells, and that TREM-1 might be directly involved in endothelial dysfunction during experimental sepsis.